Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any - 61 |
| Updated: | 2/8/2019 |
| Start Date: | April 2016 |
| End Date: | June 2019 |
Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation in Peri or Post-menopausal Women at Moderate Risk for Development of Breast Cancer
The purpose of this study is to learn whether daily use of Duavee® is accepted and tolerated
by peri- and post-menopausal women at moderate risk for development of breast cancer.
by peri- and post-menopausal women at moderate risk for development of breast cancer.
Duavee® is tissue specific estrogen complex of bazedoxifene plus conjugated estrogen which is
FDA approved for relief of menopausal symptoms and prevention of osteoporosis in women with a
uterus who have not been diagnosed with estrogen dependent neoplasia. The overall purpose of
this research is to demonstrate in a preliminary fashion that despite reduction in menopausal
symptoms, (Duavee®) does not increase and may decrease proliferation in benign breast tissue
in a cohort of peri- or post-menopausal women at moderately increased risk for breast cancer.
If this pilot shows rapid accrual, good retention, and lack of significant increase in the
risk biomarker Ki-67 in benign breast tissue, a larger prevention trial is envisioned
FDA approved for relief of menopausal symptoms and prevention of osteoporosis in women with a
uterus who have not been diagnosed with estrogen dependent neoplasia. The overall purpose of
this research is to demonstrate in a preliminary fashion that despite reduction in menopausal
symptoms, (Duavee®) does not increase and may decrease proliferation in benign breast tissue
in a cohort of peri- or post-menopausal women at moderately increased risk for breast cancer.
If this pilot shows rapid accrual, good retention, and lack of significant increase in the
risk biomarker Ki-67 in benign breast tissue, a larger prevention trial is envisioned
Inclusion Criteria:
- Women with vasomotor symptoms with a uterus who are postmenopausal or in late
menopause transition
- Body Mass Index (BMI) <36 kg/m2
- Class I-III mammogram within 6 months of Random Periareolar Fine Needle Aspiration
(RPFNA); If Class 0 or 4, must be resolved with additional procedures
- If previously on oral contraceptives or hormone replacement, off for 8 weeks or more
prior to baseline RPFNA; the exception is low dose vaginal hormones
- Confirmed moderate risk of developing breast cancer
- RPFNA results within study defined range
- Kidney and liver function within study defined range
- Willing and able to comply with study related procedures
Exclusion Criteria:
- Previous biopsy showing evidence of breast cancer
- Have a predisposition to or prior history of thromboembolism, deep venous thrombosis,
pulmonary embolism, or stroke
- History of renal or liver disease
- Prior ovarian or endometrial cancer
- Stopped or started hormone replacement within 8 weeks
- Any other condition or intercurrent illness that in the opinion of the investigator
makes the woman a poor candidate for RPFNA
- Currently taking or have taken specific medications in the past 6 months
- Participation on any chemoprevention trial within 6 months
- Current illness which would make potential participant unsuitable for enrollment
We found this trial at
2
sites
University of Kansas Medical Center The University of Kansas Medical Center serves Kansas through excellence...
Click here to add this to my saved trials
Click here to add this to my saved trials